You are viewing the site in preview mode

Skip to main content

Table 1 Characteristics at time of index blood culture by treatment group, with and without propensity score weighting

From: Early initiation of ceftaroline-based combination therapy for methicillin-resistant Staphylococcus aureus bacteremia

Characteristic

Combinationa

(n = 95)

Monotherapya

(n = 118)

P Valuesb

Combinationa (weighted)

Monotherapya

(weighted)

P Valuesb

Age, years

58.66 ± 1.49

62.96 ± 1.28

0.03

59.74 ± 1.73

61.01 ± 1.50

0.48

Female

34 (35.8)

39 (33.1)

0.68

34 (34.3)

35 (34.4)

0.52

Weight, kg

84.84 ± 2.66

87.41 ± 2.51

0.48

88.21 ± 4.12

87.08 ± 2.43

0.73

Comorbidities

      

 Diabetes

45 (47.4)

48 (40.7)

0.33

46 (45.7)

46 (45.4)

0.60

 CKD/ESRD

34 (35.8)

34 (28.8)

0.28

32 (31.7)

31 (30.7)

0.67

 Cirrhosis

9 (9.5)

11 (9.3)

0.98

8 (7.5)

10 (9.7)

0.72

 Immunocompromised

9 (21)

33 (28)

0.06

17 (17.4)

23 (23)

0.19

Charlson comorbidity indexc

3.09 ± 0.20

2.87 ± 0.20

0.44

2.98 ± 0.23

2.93 ± 0.20

0.98

Located in ICU at time of index blood culture

22 (23.2)

23 (19.5)

0.52

23 (23.3)

23 (22.8)

0.52

qPitt ≥ 2

47 (49.5)

42 (35.6)

0.04

44 (43.5)

40 (39.7)

0.83

Temperature < 36 °C

10 (10.5)

9 (7.6)

0.46

11 (10.6)

12 (11.4)

0.33

SBP < 90 mmHg or vasopressor use

42 (44.2)

27 (22.9)

< 0.01

38 (37.7)

33 (32.2)

0.93

RR ≥ 25/min or mechanically ventilated

63 (66.3)

60 (50.8)

0.02

59 (58.5)

55 (53.8)

0.36

AMS

31 (32.6)

41 (34.7)

0.75

33 (33)

33 (33)

0.74

Other anti-MRSA agentd

19 (20)

21 (17.8)

0.68

22 (21.8)

21 (20.6)

0.69

Source of infection

      

 Primary

43 (45.3)

47 (39.8)

0.43

46 (46.1)

38 (37.1)

0.17

 Secondary

39 (41.1)

55 (46.6)

0.42

40 (40.2)

52 (51.6)

0.11

 Catheter

13 (13.7)

16 (13.6)

0.98

14 (13.7)

11 (11.3)

0.50

Foci of infection

      

 Catheter

20 (21.1)

29 (24.6)

0.55

21 (21.3)

21 (21)

0.76

 Vertebral bone/joint

17 (17.9)

13 (11)

0.15

14 (14.2)

11 (10.8)

0.38

 Nonvertebral bone/joint

23 (24.2)

28 (23.7)

0.93

24 (24.3)

24 (24)

0.76

 SSTI/Surgical

39 (41.1)

45 (38.1)

0.67

41 (40.8)

41 (40.1)

0.57

 Endovascular

27 (28.4)

44 (37.3)

0.17

34 (33.5)

35 (35)

0.88

 Respiratory

31 (32.6)

15 (12.7)

< 0.01

22 (22.2)

19 (18.8)

0.68

 Hardware

16 (16.8)

24 (20.3)

0.52

17 (16.9)

19 (18.9)

0.93

Source controle

86 (90.5)

103 (87.3)

0.46

92 (91.2)

91 (89.8)

0.86

Time to initial anti-MRSA agent from index blood culture collection, hours

4.75 ± 2.27

10.44 ± 1.45

0.04

7.46 ± 2.19

9.03 ± 1.25

0.62

Anti-MRSA agent started before index blood culture collection

13 (13.7)

10 (8.5)

0.23

13 (12.6)

12 (12.3)

0.82

Time to MRSA result from initial anti-MRSA agent administration, hours

16.31 ± 2.43

15.35 ± 1.61

0.74

14.83 ± 2.08

16.74 ± 1.71

0.25

  1. Abbreviations: AMS, altered mental status; CKD/ESRD, chronic kidney disease/end stage renal disease; ICU, intensive care unit; qPitt, quick Pitt bacteremia score; RR, respiratory rate; SBP, systolic blood pressure; SSTI: skin and soft tissue infection
  2. aData are presented as No. (%) for dichotomous variables and mean ± standard deviation for continuous variables
  3. bDifference in proportions between groups performed via Pearson’s chi-square test. Continuous variables were compared with a t-test
  4. cQuan variant [28], non-age adjusted
  5. dOther anti-MRSA agent included rifampin, clindamycin, linezolid, and sulfamethoxazole/trimethoprim
  6. eIncludes partial source control
Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us